Skip to main content
Erschienen in: Virchows Archiv 6/2014

01.12.2014 | Original Article

Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases

verfasst von: Frank Bergmann, Sebastian Aulmann, Bence Sipos, Matthias Kloor, Anja von Heydebreck, Johannes Schweipert, Andreas Harjung, Philipp Mayer, Werner Hartwig, Gerhard Moldenhauer, David Capper, Gerhard Dyckhoff, Kolja Freier, Esther Herpel, Anja Schleider, Peter Schirmacher, Gunhild Mechtersheimer, Günter Klöppel, Hendrik Bläker

Erschienen in: Virchows Archiv | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic acinar cell carcinomas (PACs) are rare but are distinct aggressive neoplasms that phenotypically differ from pancreatic ductal adenocarcinomas (PDACs) and pancreatic neuroendocrine neoplasms (PNENs). Despite recent work on the genetic changes of PACs, their molecular pathogenesis is still poorly understood. In this study, we focus on a comparative genomic hybridization analysis. Based on frequent chromosomal imbalances, the involvement of DCC and c-MYC in the pathogenesis of PACs is further investigated. Moreover, we examine markers harboring potential therapeutic relevance (K-RAS, BRAF, EGFR, MGMT, HSP90, L1CAM, Her2). PACs revealed a microsatellite stable, chromosomal unstable genotype, defined by recurrent chromosomal losses of 1p, 3p, 4q, 5q, 6q, 8p, 9p, 11q, 13q, 16q, and 18, as well as gains of 1q, 7, 8q, 12, 17q, and 20q. Subsets of PAC displayed reduction/loss of DCC (79 %) and c-MYC-amplification (17 %). Significant EGFR expression occurred in 42 %, HSP90 expression in 98 %, L1CAM expression in 72 %, and loss of MGMT in 26 %. Two cases carried a K-RAS mutation. Mutations of EGFR or BRAF were not detected. All cases were Her2/neu-negative. PACs display characteristic chromosomal imbalances which are distinctly different from those in pancreatic ductal adenocarcinomas and pancreatic neuroendocrine neoplasms. Our findings suggest that DCC and c-MYC alterations may play an important role in the pathogenesis of PACs. Furthermore, EGFR, MGMT, HSP90, and L1CAM may be useful as therapeutic markers and predictors of response to therapy in a subset of PACs.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY (2008) Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg 12(12):2078–2086. doi:10.1007/s11605-008-0705-6 PubMedCrossRef Schmidt CM, Matos JM, Bentrem DJ, Talamonti MS, Lillemoe KD, Bilimoria KY (2008) Acinar cell carcinoma of the pancreas in the United States: prognostic factors and comparison to ductal adenocarcinoma. J Gastrointest Surg 12(12):2078–2086. doi:10.​1007/​s11605-008-0705-6 PubMedCrossRef
3.
Zurück zum Zitat Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M (2007) Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from pancreatic cancer registry of Japan pancreas society. Pancreas 35(1):42–46. doi:10.1097/mpa.0b013e31804bfbd3 PubMedCrossRef Kitagami H, Kondo S, Hirano S, Kawakami H, Egawa S, Tanaka M (2007) Acinar cell carcinoma of the pancreas: clinical analysis of 115 patients from pancreatic cancer registry of Japan pancreas society. Pancreas 35(1):42–46. doi:10.​1097/​mpa.​0b013e31804bfbd3​ PubMedCrossRef
4.
Zurück zum Zitat Klimstra DS, Heffess CS, Oertel JE, Rosai J (1992) Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol 16(9):815–837PubMedCrossRef Klimstra DS, Heffess CS, Oertel JE, Rosai J (1992) Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol 16(9):815–837PubMedCrossRef
5.
Zurück zum Zitat Osborne BM, Culbert SJ, Cangir A, MacKay B (1977) Acinar cell carcinoma of the pancreas in a 9-year-old child: case report with electron microscopic observations. South Med J 70(3):370–372PubMedCrossRef Osborne BM, Culbert SJ, Cangir A, MacKay B (1977) Acinar cell carcinoma of the pancreas in a 9-year-old child: case report with electron microscopic observations. South Med J 70(3):370–372PubMedCrossRef
7.
Zurück zum Zitat Klimstra DS, Hruban RH, Klöppel G, Morohoshi T, Ohike N (2010) Acinar cell neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digestive system. International Agency for Research on Cancer, Lyon, pp 314–318 Klimstra DS, Hruban RH, Klöppel G, Morohoshi T, Ohike N (2010) Acinar cell neoplasms of the pancreas. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of the digestive system. International Agency for Research on Cancer, Lyon, pp 314–318
8.
Zurück zum Zitat La Rosa S, Adsay V, Albarello L, Asioli S, Casnedi S, Franzi F, Marando A, Notohara K, Sessa F, Vanoli A, Zhang L, Capella C (2012) Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers. Am J Surg Pathol 36(12):1782–1795. doi:10.1097/PAS.0b013e318263209d PubMedCrossRef La Rosa S, Adsay V, Albarello L, Asioli S, Casnedi S, Franzi F, Marando A, Notohara K, Sessa F, Vanoli A, Zhang L, Capella C (2012) Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers. Am J Surg Pathol 36(12):1782–1795. doi:10.​1097/​PAS.​0b013e318263209d​ PubMedCrossRef
9.
Zurück zum Zitat Colombo P, Arizzi C, Roncalli M (2004) Acinar cell cystadenocarcinoma of the pancreas: report of rare case and review of the literature. Hum Pathol 35(12):1568–1571PubMedCrossRef Colombo P, Arizzi C, Roncalli M (2004) Acinar cell cystadenocarcinoma of the pancreas: report of rare case and review of the literature. Hum Pathol 35(12):1568–1571PubMedCrossRef
10.
Zurück zum Zitat Stelow EB, Shaco-Levy R, Bao F, Garcia J, Klimstra DS (2010) Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol 34(4):510–518. doi:10.1097/PAS.0b013e3181cfcac7 PubMedCrossRef Stelow EB, Shaco-Levy R, Bao F, Garcia J, Klimstra DS (2010) Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. Am J Surg Pathol 34(4):510–518. doi:10.​1097/​PAS.​0b013e3181cfcac7​ PubMedCrossRef
11.
12.
Zurück zum Zitat Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, Conlon K, Brennan M, Cameron JL, Klimstra DS (2002) Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 160(3):953–962PubMedCentralPubMedCrossRef Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, Conlon K, Brennan M, Cameron JL, Klimstra DS (2002) Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 160(3):953–962PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Rigaud G, Moore PS, Zamboni G, Orlandini S, Taruscio D, Paradisi S, Lemoine NR, Kloppel G, Scarpa A (2000) Allelotype of pancreatic acinar cell carcinoma. Int J Cancer 88(5):772–777PubMedCrossRef Rigaud G, Moore PS, Zamboni G, Orlandini S, Taruscio D, Paradisi S, Lemoine NR, Kloppel G, Scarpa A (2000) Allelotype of pancreatic acinar cell carcinoma. Int J Cancer 88(5):772–777PubMedCrossRef
14.
Zurück zum Zitat Terhune PG, Heffess CS, Longnecker DS (1994) Only wild-type c-Ki-ras codons 12, 13, and 61 in human pancreatic acinar cell carcinomas. Mol Carcinog 10(2):110–114PubMedCrossRef Terhune PG, Heffess CS, Longnecker DS (1994) Only wild-type c-Ki-ras codons 12, 13, and 61 in human pancreatic acinar cell carcinomas. Mol Carcinog 10(2):110–114PubMedCrossRef
15.
Zurück zum Zitat Hoorens A, Lemoine NR, McLellan E, Morohoshi T, Kamisawa T, Heitz PU, Stamm B, Ruschoff J, Wiedenmann B, Kloppel G (1993) Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol 143(3):685–698PubMedCentralPubMed Hoorens A, Lemoine NR, McLellan E, Morohoshi T, Kamisawa T, Heitz PU, Stamm B, Ruschoff J, Wiedenmann B, Kloppel G (1993) Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol 143(3):685–698PubMedCentralPubMed
16.
Zurück zum Zitat Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN (1994) K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54(6):1556–1560PubMed Pellegata NS, Sessa F, Renault B, Bonato M, Leone BE, Solcia E, Ranzani GN (1994) K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res 54(6):1556–1560PubMed
17.
Zurück zum Zitat Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, Bassi C, Lemoine NR, Scarpa A (2001) Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 84(2):253–262. doi:10.1054/bjoc.2000.1567 PubMedCentralPubMedCrossRef Moore PS, Orlandini S, Zamboni G, Capelli P, Rigaud G, Falconi M, Bassi C, Lemoine NR, Scarpa A (2001) Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. Br J Cancer 84(2):253–262. doi:10.​1054/​bjoc.​2000.​1567 PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat de Wilde RF, Ottenhof NA, Jansen M, Morsink FH, de Leng WW, Offerhaus GJ, Brosens LA (2011) Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. Mod Pathol 24(9):1229–1236. doi:10.1038/modpathol.2011.83 PubMedCrossRef de Wilde RF, Ottenhof NA, Jansen M, Morsink FH, de Leng WW, Offerhaus GJ, Brosens LA (2011) Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. Mod Pathol 24(9):1229–1236. doi:10.​1038/​modpathol.​2011.​83 PubMedCrossRef
19.
Zurück zum Zitat Jiao Y, Yonescu R, Offerhaus GJ, Klimstra DS, Maitra A, Eshleman JR, Herman JG, Poh W, Pelosof L, Wolfgang CL, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N, Wood LD (2014) Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 232(4):428–435. doi:10.1002/path.4310 PubMedCentralPubMedCrossRef Jiao Y, Yonescu R, Offerhaus GJ, Klimstra DS, Maitra A, Eshleman JR, Herman JG, Poh W, Pelosof L, Wolfgang CL, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N, Wood LD (2014) Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 232(4):428–435. doi:10.​1002/​path.​4310 PubMedCentralPubMedCrossRef
20.
Zurück zum Zitat Furlan D, Sahnane N, Bernasconi B, Frattini M, Tibiletti MG, Molinari F, Marando A, Zhang L, Vanoli A, Casnedi S, Adsay V, Notohara K, Albarello L, Asioli S, Sessa F, Capella C, La Rosa S (2014) APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation. Virchows Arch. doi:10.1007/s00428-014-1562-1 PubMed Furlan D, Sahnane N, Bernasconi B, Frattini M, Tibiletti MG, Molinari F, Marando A, Zhang L, Vanoli A, Casnedi S, Adsay V, Notohara K, Albarello L, Asioli S, Sessa F, Capella C, La Rosa S (2014) APC alterations are frequently involved in the pathogenesis of acinar cell carcinoma of the pancreas, mainly through gene loss and promoter hypermethylation. Virchows Arch. doi:10.​1007/​s00428-014-1562-1 PubMed
21.
Zurück zum Zitat Abraham SC, Wu TT, Klimstra DS, Finn LS, Lee JH, Yeo CJ, Cameron JL, Hruban RH (2001) Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 159(5):1619–1627PubMedCentralPubMedCrossRef Abraham SC, Wu TT, Klimstra DS, Finn LS, Lee JH, Yeo CJ, Cameron JL, Hruban RH (2001) Distinctive molecular genetic alterations in sporadic and familial adenomatous polyposis-associated pancreatoblastomas: frequent alterations in the APC/beta-catenin pathway and chromosome 11p. Am J Pathol 159(5):1619–1627PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Kitoh H, Ryozawa S, Harada T, Kondoh S, Furuya T, Kawauchi S, Oga A, Okita K, Sasaki K (2005) Comparative genomic hybridization analysis for pancreatic cancer specimens obtained by endoscopic ultrasonography-guided fine-needle aspiration. J Gastroenterol 40(5):511–517. doi:10.1007/s00535-005-1577-0 PubMedCrossRef Kitoh H, Ryozawa S, Harada T, Kondoh S, Furuya T, Kawauchi S, Oga A, Okita K, Sasaki K (2005) Comparative genomic hybridization analysis for pancreatic cancer specimens obtained by endoscopic ultrasonography-guided fine-needle aspiration. J Gastroenterol 40(5):511–517. doi:10.​1007/​s00535-005-1577-0 PubMedCrossRef
23.
Zurück zum Zitat Taruscio D, Paradisi S, Zamboni G, Rigaud G, Falconi M, Scarpa A (2000) Pancreatic acinar carcinoma shows a distinct pattern of chromosomal imbalances by comparative genomic hybridization. Genes Chromosomes Cancer 28(3):294–299PubMedCrossRef Taruscio D, Paradisi S, Zamboni G, Rigaud G, Falconi M, Scarpa A (2000) Pancreatic acinar carcinoma shows a distinct pattern of chromosomal imbalances by comparative genomic hybridization. Genes Chromosomes Cancer 28(3):294–299PubMedCrossRef
24.
Zurück zum Zitat Rieker RJ, Aulmann S, Penzel R, Schnabel PA, Blaeker H, Esposito I, Morresi-Hauf A, Otto HF, Hecker E, Dienemann H, Schirmacher P, Mechtersheimer G (2005) Chromosomal imbalances in sporadic neuroendocrine tumours of the thymus. Cancer Lett 223(1):169–174. doi:10.1016/j.canlet.2004.10.027 PubMedCrossRef Rieker RJ, Aulmann S, Penzel R, Schnabel PA, Blaeker H, Esposito I, Morresi-Hauf A, Otto HF, Hecker E, Dienemann H, Schirmacher P, Mechtersheimer G (2005) Chromosomal imbalances in sporadic neuroendocrine tumours of the thymus. Cancer Lett 223(1):169–174. doi:10.​1016/​j.​canlet.​2004.​10.​027 PubMedCrossRef
25.
Zurück zum Zitat Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M (2006) Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol 37(8):1000–1008. doi:10.1016/j.humpath.2006.03.014 PubMedCrossRef Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M (2006) Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol 37(8):1000–1008. doi:10.​1016/​j.​humpath.​2006.​03.​014 PubMedCrossRef
27.
Zurück zum Zitat Warth A, Penzel R, Brandt R, Sers C, Fischer JR, Thomas M, Herth FJ, Dietel M, Schirmacher P, Blaker H (2012) Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch 460(4):407–414. doi:10.1007/s00428-012-1219-x PubMedCrossRef Warth A, Penzel R, Brandt R, Sers C, Fischer JR, Thomas M, Herth FJ, Dietel M, Schirmacher P, Blaker H (2012) Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch 460(4):407–414. doi:10.​1007/​s00428-012-1219-x PubMedCrossRef
28.
Zurück zum Zitat Findeisen P, Kloor M, Merx S, Sutter C, Woerner SM, Dostmann N, Benner A, Dondog B, Pawlita M, Dippold W, Wagner R, Gebert J, von Knebel DM (2005) T25 repeat in the 3′ untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res 65(18):8072–8078. doi:10.1158/0008-5472.CAN-04-4146 PubMedCrossRef Findeisen P, Kloor M, Merx S, Sutter C, Woerner SM, Dostmann N, Benner A, Dondog B, Pawlita M, Dippold W, Wagner R, Gebert J, von Knebel DM (2005) T25 repeat in the 3′ untranslated region of the CASP2 gene: a sensitive and specific marker for microsatellite instability in colorectal cancer. Cancer Res 65(18):8072–8078. doi:10.​1158/​0008-5472.​CAN-04-4146 PubMedCrossRef
29.
Zurück zum Zitat Gunawan B, von Heydebreck A, Fritsch T, Huber W, Ringert RH, Jakse G, Fuzesi L (2003) Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res 63(19):6200–6205PubMed Gunawan B, von Heydebreck A, Fritsch T, Huber W, Ringert RH, Jakse G, Fuzesi L (2003) Cytogenetic and morphologic typing of 58 papillary renal cell carcinomas: evidence for a cytogenetic evolution of type 2 from type 1 tumors. Cancer Res 63(19):6200–6205PubMed
30.
Zurück zum Zitat Gunawan B, von Heydebreck A, Sander B, Schulten HJ, Haller F, Langer C, Armbrust T, Bollmann M, Gasparov S, Kovac D, Fuzesi L (2007) An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications. J Pathol 211(4):463–470. doi:10.1002/path.2128 PubMedCrossRef Gunawan B, von Heydebreck A, Sander B, Schulten HJ, Haller F, Langer C, Armbrust T, Bollmann M, Gasparov S, Kovac D, Fuzesi L (2007) An oncogenetic tree model in gastrointestinal stromal tumours (GISTs) identifies different pathways of cytogenetic evolution with prognostic implications. J Pathol 211(4):463–470. doi:10.​1002/​path.​2128 PubMedCrossRef
32.
Zurück zum Zitat Harada T, Okita K, Shiraishi K, Kusano N, Furuya T, Oga A, Kawauchi S, Kondoh S, Sasaki K (2002) Detection of genetic alterations in pancreatic cancers by comparative genomic hybridization coupled with tissue microdissection and degenerate oligonucleotide primed polymerase chain reaction. Oncology 62(3):251–258PubMedCrossRef Harada T, Okita K, Shiraishi K, Kusano N, Furuya T, Oga A, Kawauchi S, Kondoh S, Sasaki K (2002) Detection of genetic alterations in pancreatic cancers by comparative genomic hybridization coupled with tissue microdissection and degenerate oligonucleotide primed polymerase chain reaction. Oncology 62(3):251–258PubMedCrossRef
33.
Zurück zum Zitat Mahlamaki EH, Hoglund M, Gorunova L, Karhu R, Dawiskiba S, Andren-Sandberg A, Kallioniemi OP, Johansson B (1997) Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Gene Chromosome Cancer 20(4):383–391CrossRef Mahlamaki EH, Hoglund M, Gorunova L, Karhu R, Dawiskiba S, Andren-Sandberg A, Kallioniemi OP, Johansson B (1997) Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer. Gene Chromosome Cancer 20(4):383–391CrossRef
35.
Zurück zum Zitat Shiraishi K, Okita K, Kusano N, Harada T, Kondoh S, Okita S, Ryozawa S, Ohmura R, Noguchi T, Iida Y, Akiyama T, Oga A, Fukumoto Y, Furuya T, Kawauchi S, Sasaki K (2001) A comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. Oncology 60(2):151–161 Shiraishi K, Okita K, Kusano N, Harada T, Kondoh S, Okita S, Ryozawa S, Ohmura R, Noguchi T, Iida Y, Akiyama T, Oga A, Fukumoto Y, Furuya T, Kawauchi S, Sasaki K (2001) A comparison of DNA copy number changes detected by comparative genomic hybridization in malignancies of the liver, biliary tract and pancreas. Oncology 60(2):151–161
36.
Zurück zum Zitat Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M, Kobari M, Horii A (1997) Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 19(3):161–169PubMedCrossRef Fukushige S, Waldman FM, Kimura M, Abe T, Furukawa T, Sunamura M, Kobari M, Horii A (1997) Frequent gain of copy number on the long arm of chromosome 20 in human pancreatic adenocarcinoma. Genes Chromosomes Cancer 19(3):161–169PubMedCrossRef
37.
Zurück zum Zitat Zhao J, Moch H, Scheidweiler AF, Baer A, Schaffer AA, Speel EJ, Roth J, Heitz PU, Komminoth P (2001) Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 32(4):364–372PubMedCrossRef Zhao J, Moch H, Scheidweiler AF, Baer A, Schaffer AA, Speel EJ, Roth J, Heitz PU, Komminoth P (2001) Genomic imbalances in the progression of endocrine pancreatic tumors. Genes Chromosomes Cancer 32(4):364–372PubMedCrossRef
38.
Zurück zum Zitat Speel EJ, Richter J, Moch H, Egenter C, Saremaslani P, Rutimann K, Zhao J, Barghorn A, Roth J, Heitz PU, Komminoth P (1999) Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 155(6):1787–1794PubMedCentralPubMedCrossRef Speel EJ, Richter J, Moch H, Egenter C, Saremaslani P, Rutimann K, Zhao J, Barghorn A, Roth J, Heitz PU, Komminoth P (1999) Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization. Am J Pathol 155(6):1787–1794PubMedCentralPubMedCrossRef
40.
Zurück zum Zitat Tonnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W, Wiedenmann B (2001) Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 48(4):536–541PubMedCentralPubMedCrossRef Tonnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W, Wiedenmann B (2001) Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 48(4):536–541PubMedCentralPubMedCrossRef
41.
Zurück zum Zitat Pourani J, Kaserer K, Pfragner R (2002) Cytogenetic and molecular analyses of multiple endocrine neoplasias of the MEN1 syndrome. Int J Oncol 20(5):971–976PubMed Pourani J, Kaserer K, Pfragner R (2002) Cytogenetic and molecular analyses of multiple endocrine neoplasias of the MEN1 syndrome. Int J Oncol 20(5):971–976PubMed
42.
Zurück zum Zitat Liu XP, Li DY, Liu XL, Xu JD, Furuya T, Kawauchi S, Oga A, Sasaki K (2009) Comparison of chromosomal aberrations between primary tumors and their synchronous lymph-node metastases in intestinal-type gastric carcinoma. Pathol Res Pract 205(2):105–111. doi:10.1016/j.prp.2008.09.003 PubMedCrossRef Liu XP, Li DY, Liu XL, Xu JD, Furuya T, Kawauchi S, Oga A, Sasaki K (2009) Comparison of chromosomal aberrations between primary tumors and their synchronous lymph-node metastases in intestinal-type gastric carcinoma. Pathol Res Pract 205(2):105–111. doi:10.​1016/​j.​prp.​2008.​09.​003 PubMedCrossRef
43.
Zurück zum Zitat Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, Grabsch HI, van de Velde CJ, Carvalho B, Meijer GA (2009) High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch 455(3):213–223. doi:10.1007/s00428-009-0814-y PubMedCentralPubMedCrossRef Buffart TE, van Grieken NC, Tijssen M, Coffa J, Ylstra B, Grabsch HI, van de Velde CJ, Carvalho B, Meijer GA (2009) High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancers. Virchows Arch 455(3):213–223. doi:10.​1007/​s00428-009-0814-y PubMedCentralPubMedCrossRef
44.
Zurück zum Zitat Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396(6712):699–703. doi:10.1038/25387 PubMedCrossRef Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A (1998) Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396(6712):699–703. doi:10.​1038/​25387 PubMedCrossRef
45.
Zurück zum Zitat Aubele M, Auer G, Braselmann H, Nahrig J, Zitzelsberger H, Quintanilla-Martinez L, Smida J, Walch A, Hofler H, Werner M (2002) Chromosomal imbalances are associated with metastasis-free survival in breast cancer patients. Anal Cell Pathol 24(2–3):77–87PubMed Aubele M, Auer G, Braselmann H, Nahrig J, Zitzelsberger H, Quintanilla-Martinez L, Smida J, Walch A, Hofler H, Werner M (2002) Chromosomal imbalances are associated with metastasis-free survival in breast cancer patients. Anal Cell Pathol 24(2–3):77–87PubMed
46.
Zurück zum Zitat Kimura Y, Noguchi T, Kawahara K, Kashima K, Daa T, Yokoyama S (2004) Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. Mod Pathol 17(11):1328–1337. doi:10.1038/modpathol.3800180 PubMedCrossRef Kimura Y, Noguchi T, Kawahara K, Kashima K, Daa T, Yokoyama S (2004) Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: gain of 20q and loss of 18q are associated with tumor progression. Mod Pathol 17(11):1328–1337. doi:10.​1038/​modpathol.​3800180 PubMedCrossRef
47.
Zurück zum Zitat Kang JU, Kang JJ, Kwon KC, Park JW, Jeong TE, Noh SM, Koo SH (2006) Genetic alterations in primary gastric carcinomas correlated with clinicopathological variables by array comparative genomic hybridization. J Korean Med Sci 21(4):656–665PubMedCentralPubMedCrossRef Kang JU, Kang JJ, Kwon KC, Park JW, Jeong TE, Noh SM, Koo SH (2006) Genetic alterations in primary gastric carcinomas correlated with clinicopathological variables by array comparative genomic hybridization. J Korean Med Sci 21(4):656–665PubMedCentralPubMedCrossRef
48.
49.
Zurück zum Zitat Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmen J, Yekebas EF, Izbicki JR, Brakenhoff RH, Streichert T, Riethdorf S, Glatzel M, Ylstra B, Pantel K, Wikman H (2009) Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res 15(5):1566–1574. doi:10.1158/1078-0432.ccr-08-2188 PubMedCrossRef Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmen J, Yekebas EF, Izbicki JR, Brakenhoff RH, Streichert T, Riethdorf S, Glatzel M, Ylstra B, Pantel K, Wikman H (2009) Genomic profiles associated with early micrometastasis in lung cancer: relevance of 4q deletion. Clin Cancer Res 15(5):1566–1574. doi:10.​1158/​1078-0432.​ccr-08-2188 PubMedCrossRef
51.
Zurück zum Zitat Fazeli A, Dickinson SL, Hermiston ML, Tighe RV, Steen RG, Small CG, Stoeckli ET, Keino-Masu K, Masu M, Rayburn H, Simons J, Bronson RT, Gordon JI, Tessier-Lavigne M, Weinberg RA (1997) Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature 386(6627):796–804. doi:10.1038/386796a0 PubMedCrossRef Fazeli A, Dickinson SL, Hermiston ML, Tighe RV, Steen RG, Small CG, Stoeckli ET, Keino-Masu K, Masu M, Rayburn H, Simons J, Bronson RT, Gordon JI, Tessier-Lavigne M, Weinberg RA (1997) Phenotype of mice lacking functional Deleted in colorectal cancer (Dcc) gene. Nature 386(6627):796–804. doi:10.​1038/​386796a0 PubMedCrossRef
52.
Zurück zum Zitat Tarafa G, Villanueva A, Farre L, Rodriguez J, Musulen E, Reyes G, Seminago R, Olmedo E, Paules AB, Peinado MA, Bachs O, Capella G (2000) DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination. Oncogene 19(4):546–555. doi:10.1038/sj.onc.1203353 PubMedCrossRef Tarafa G, Villanueva A, Farre L, Rodriguez J, Musulen E, Reyes G, Seminago R, Olmedo E, Paules AB, Peinado MA, Bachs O, Capella G (2000) DCC and SMAD4 alterations in human colorectal and pancreatic tumor dissemination. Oncogene 19(4):546–555. doi:10.​1038/​sj.​onc.​1203353 PubMedCrossRef
53.
Zurück zum Zitat Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, Tessier-Lavigne M (1996) Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell 87(2):175–185PubMedCrossRef Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, Tessier-Lavigne M (1996) Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell 87(2):175–185PubMedCrossRef
54.
Zurück zum Zitat Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U (2002) c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol 15(4):462–469. doi:10.1038/modpathol.3880547 PubMedCrossRef Schleger C, Verbeke C, Hildenbrand R, Zentgraf H, Bleyl U (2002) c-MYC activation in primary and metastatic ductal adenocarcinoma of the pancreas: incidence, mechanisms, and clinical significance. Mod Pathol 15(4):462–469. doi:10.​1038/​modpathol.​3880547 PubMedCrossRef
55.
Zurück zum Zitat Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, Saltz LB (2002) Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 20(24):4673–4678PubMedCrossRef Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, Saltz LB (2002) Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 20(24):4673–4678PubMedCrossRef
56.
Zurück zum Zitat Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757–1765. doi:10.1056/NEJMoa0804385 PubMedCrossRef Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17):1757–1765. doi:10.​1056/​NEJMoa0804385 PubMedCrossRef
58.
Zurück zum Zitat Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS (2009) O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15(1):338–345. doi:10.1158/1078-0432.CCR-08-1476 PubMedCentralPubMedCrossRef Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, Meyerhardt JA, Clark JW, Stuart K, Fuchs CS, Redston MS (2009) O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 15(1):338–345. doi:10.​1158/​1078-0432.​CCR-08-1476 PubMedCentralPubMedCrossRef
59.
Zurück zum Zitat Mayer P, Harjung A, Breinig M, Fischer L, Ehemann V, Malz M, Scherubl H, Britsch S, Werner J, Kern MA, Blaker H, Schirmacher P, Bergmann F (2012) Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors. Endocr Relat Cancer 19(3):217–232. doi:10.1530/ERC-11-0227 PubMedCrossRef Mayer P, Harjung A, Breinig M, Fischer L, Ehemann V, Malz M, Scherubl H, Britsch S, Werner J, Kern MA, Blaker H, Schirmacher P, Bergmann F (2012) Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors. Endocr Relat Cancer 19(3):217–232. doi:10.​1530/​ERC-11-0227 PubMedCrossRef
60.
Zurück zum Zitat Song D, Chaerkady R, Tan AC, Garcia-Garcia E, Nalli A, Suarez-Gauthier A, Lopez-Rios F, Zhang XF, Solomon A, Tong J, Read M, Fritz C, Jimeno A, Pandey A, Hidalgo M (2008) Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther 7(10):3275–3284. doi:10.1158/1535-7163.MCT-08-0508 PubMedCrossRef Song D, Chaerkady R, Tan AC, Garcia-Garcia E, Nalli A, Suarez-Gauthier A, Lopez-Rios F, Zhang XF, Solomon A, Tong J, Read M, Fritz C, Jimeno A, Pandey A, Hidalgo M (2008) Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther 7(10):3275–3284. doi:10.​1158/​1535-7163.​MCT-08-0508 PubMedCrossRef
61.
Zurück zum Zitat Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA (2005) In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 56(2):115–125. doi:10.1007/s00280-004-0939-2 PubMedCrossRef Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, Sausville EA (2005) In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 56(2):115–125. doi:10.​1007/​s00280-004-0939-2 PubMedCrossRef
62.
Zurück zum Zitat Usmani SZ, Bona R, Li Z (2009) 17 AAG for HSP90 inhibition in cancer—from bench to bedside. Curr Mol Med 9(5):654–664PubMedCrossRef Usmani SZ, Bona R, Li Z (2009) 17 AAG for HSP90 inhibition in cancer—from bench to bedside. Curr Mol Med 9(5):654–664PubMedCrossRef
64.
Zurück zum Zitat Bergmann F, Wandschneider F, Sipos B, Moldenhauer G, Schniewind B, Welsch T, Schirrmacher P, Kloppel G, Altevogt P, Schafer H, Sebens Muerkoster S (2010) Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol Rep 24(4):909–915PubMed Bergmann F, Wandschneider F, Sipos B, Moldenhauer G, Schniewind B, Welsch T, Schirrmacher P, Kloppel G, Altevogt P, Schafer H, Sebens Muerkoster S (2010) Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncol Rep 24(4):909–915PubMed
65.
Zurück zum Zitat Bergmann F, Moldenhauer G, Herpel E, Gaida MM, Strobel O, Werner J, Esposito I, Muerkoster SS, Schirmacher P, Kern MA (2010) Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets? Histopathology 56(4):440–448. doi:10.1111/j.1365-2559.2010.03499.x PubMedCrossRef Bergmann F, Moldenhauer G, Herpel E, Gaida MM, Strobel O, Werner J, Esposito I, Muerkoster SS, Schirmacher P, Kern MA (2010) Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets? Histopathology 56(4):440–448. doi:10.​1111/​j.​1365-2559.​2010.​03499.​x PubMedCrossRef
66.
Zurück zum Zitat Kaifi JT, Zinnkann U, Yekebas EF, Schurr PG, Reichelt U, Wachowiak R, Fiegel HC, Petri S, Schachner M, Izbicki JR (2006) L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. World J Gastroenterol 12(1):94–98PubMedCentralPubMed Kaifi JT, Zinnkann U, Yekebas EF, Schurr PG, Reichelt U, Wachowiak R, Fiegel HC, Petri S, Schachner M, Izbicki JR (2006) L1 is a potential marker for poorly-differentiated pancreatic neuroendocrine carcinoma. World J Gastroenterol 12(1):94–98PubMedCentralPubMed
67.
Zurück zum Zitat Gast D, Riedle S, Riedle S, Schabath H, Schlich S, Schneider A, Issa Y, Stoeck A, Fogel M, Joumaa S, Wenger T, Herr I, Gutwein P, Altevogt P (2005) L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas. Int J Cancer 115(4):658–665. doi:10.1002/ijc.20869 PubMedCrossRef Gast D, Riedle S, Riedle S, Schabath H, Schlich S, Schneider A, Issa Y, Stoeck A, Fogel M, Joumaa S, Wenger T, Herr I, Gutwein P, Altevogt P (2005) L1 augments cell migration and tumor growth but not beta3 integrin expression in ovarian carcinomas. Int J Cancer 115(4):658–665. doi:10.​1002/​ijc.​20869 PubMedCrossRef
68.
Zurück zum Zitat Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, Ben-Ze’ev A (2005) L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168(4):633–642. doi:10.1083/jcb.200408051 PubMedCentralPubMedCrossRef Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, Ben-Ze’ev A (2005) L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168(4):633–642. doi:10.​1083/​jcb.​200408051 PubMedCentralPubMedCrossRef
69.
Zurück zum Zitat Kaifi JT, Strelow A, Schurr PG, Reichelt U, Yekebas EF, Wachowiak R, Quaas A, Strate T, Schaefer H, Sauter G, Schachner M, Izbicki JR (2006) L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol 19(3):399–406. doi:10.1038/modpathol.3800547 PubMedCrossRef Kaifi JT, Strelow A, Schurr PG, Reichelt U, Yekebas EF, Wachowiak R, Quaas A, Strate T, Schaefer H, Sauter G, Schachner M, Izbicki JR (2006) L1 (CD171) is highly expressed in gastrointestinal stromal tumors. Mod Pathol 19(3):399–406. doi:10.​1038/​modpathol.​3800547 PubMedCrossRef
70.
Zurück zum Zitat Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW, Moon HY (2007) L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol 14(5):1703–1711. doi:10.1245/s10434-006-9281-8 PubMedCrossRef Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW, Moon HY (2007) L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol 14(5):1703–1711. doi:10.​1245/​s10434-006-9281-8 PubMedCrossRef
71.
Zurück zum Zitat Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P, Gutwein P (2003) L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett 189(2):237–247PubMedCrossRef Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P, Gutwein P (2003) L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Lett 189(2):237–247PubMedCrossRef
72.
Zurück zum Zitat Issa Y, Nummer D, Seibel T, Muerkoster SS, Koch M, Schmitz-Winnenthal FH, Galindo L, Weitz J, Beckhove P, Altevogt P (2009) Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. J Mol Med 87(1):99–112. doi:10.1007/s00109-008-0410-7 PubMedCrossRef Issa Y, Nummer D, Seibel T, Muerkoster SS, Koch M, Schmitz-Winnenthal FH, Galindo L, Weitz J, Beckhove P, Altevogt P (2009) Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. J Mol Med 87(1):99–112. doi:10.​1007/​s00109-008-0410-7 PubMedCrossRef
73.
Zurück zum Zitat Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP, Arlt M, Moldenhauer G, Fogel M, Kruger A, Altevogt P (2008) The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 27(9):1281–1289. doi:10.1038/sj.onc.1210747 PubMedCrossRef Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP, Arlt M, Moldenhauer G, Fogel M, Kruger A, Altevogt P (2008) The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. Oncogene 27(9):1281–1289. doi:10.​1038/​sj.​onc.​1210747 PubMedCrossRef
74.
Zurück zum Zitat Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, Honer M, Schubiger PA, Altevogt P, Kruger A (2006) Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 66(2):936–943. doi:10.1158/0008-5472.CAN-05-1818 PubMedCrossRef Arlt MJ, Novak-Hofer I, Gast D, Gschwend V, Moldenhauer G, Grunberg J, Honer M, Schubiger PA, Altevogt P, Kruger A (2006) Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 66(2):936–943. doi:10.​1158/​0008-5472.​CAN-05-1818 PubMedCrossRef
75.
Zurück zum Zitat Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, Group B-S (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. doi:10.1056/NEJMoa1103782 PubMedCentralPubMedCrossRef Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, Group B-S (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516. doi:10.​1056/​NEJMoa1103782 PubMedCentralPubMedCrossRef
76.
Zurück zum Zitat Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:10.1056/NEJM200103153441101 PubMedCrossRef Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792. doi:10.​1056/​NEJM200103153441​101 PubMedCrossRef
Metadaten
Titel
Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases
verfasst von
Frank Bergmann
Sebastian Aulmann
Bence Sipos
Matthias Kloor
Anja von Heydebreck
Johannes Schweipert
Andreas Harjung
Philipp Mayer
Werner Hartwig
Gerhard Moldenhauer
David Capper
Gerhard Dyckhoff
Kolja Freier
Esther Herpel
Anja Schleider
Peter Schirmacher
Gunhild Mechtersheimer
Günter Klöppel
Hendrik Bläker
Publikationsdatum
01.12.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Virchows Archiv / Ausgabe 6/2014
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-014-1657-8

Weitere Artikel der Ausgabe 6/2014

Virchows Archiv 6/2014 Zur Ausgabe

Neu im Fachgebiet Pathologie